Skip to main content
Journal cover image

Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns.

Publication ,  Journal Article
Gosnell, HL; Roberts, DE; Zhang, X; Azzato, EM; Jacubowski, MA; Toro, P; Corredor, G; Cheng, Y-W; Dermawan, J; Calderaro, J; Graham, RP ...
Published in: Am J Clin Pathol
December 1, 2025

OBJECTIVE: β-Catenin-mutated hepatocellular adenomas (HCAs) carry an increased malignant transformation risk and are screened by interpreting glutamine synthetase (GS) and β-catenin by immunohistochemistry (IHC). Our study aims to assess GS and β-catenin interpretation guidelines for applicability and reproducibility in predicting high-risk HCA and other relevant molecular alterations. METHODS: Hematoxylin and eosin (H&E), β-catenin, GS, and CD34 stains from 75 HCAs were interpreted by three pathologists using Method A (GS interpretation: negative, perivenular patchy, map-like, diffuse, and indeterminate) and Method B criteria (similar GS interpretation scheme based on a recent publication, with and without CD34 expression patterns). Ease of application and interpretation confidence level were assessed. High-risk IHC was defined as nuclear β-catenin and/or diffuse homogeneous GS. Molecular testing was performed on a subset of HCAs and controls. RESULTS: There were 57 resections and 18 biopsy specimens examined. Methods A and B (GS only) were rated as easy to apply, with high interpretation confidence (≥90% using both methods). Consensus rate was comparable in biopsy specimens (100% for both methods) and resections (88% for Method A, 93% for Method B). While the same cases were stratified into high-risk GS categories using both systems, clinically significant genetic alterations (TERT promoter, EGFR, MTOR, and TP53) were identified in 25% of cases stratified as not high risk by IHC. CONCLUSIONS: Both methods have a similar ease of application and level of interpretation confidence, and they also detected β-catenin mutations as expected. Other relevant molecular alterations associated with risk of neoplastic progression and/or bleeding were detected in 25% of HCAs with the non-high-risk IHC phenotype, suggesting the value of molecular testing in this subset.

Duke Scholars

Published In

Am J Clin Pathol

DOI

EISSN

1943-7722

Publication Date

December 1, 2025

Volume

164

Issue

6

Start / End Page

908 / 916

Location

England

Related Subject Headings

  • beta Catenin
  • Pathology
  • Mutation
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Immunohistochemistry
  • Humans
  • Glutamate-Ammonia Ligase
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gosnell, H. L., Roberts, D. E., Zhang, X., Azzato, E. M., Jacubowski, M. A., Toro, P., … Allende, D. S. (2025). Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns. Am J Clin Pathol, 164(6), 908–916. https://doi.org/10.1093/ajcp/aqaf115
Gosnell, Hailey L., Daniel E. Roberts, Xuefeng Zhang, Elizabeth M. Azzato, Maureen A. Jacubowski, Paula Toro, Germán Corredor, et al. “Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns.Am J Clin Pathol 164, no. 6 (December 1, 2025): 908–16. https://doi.org/10.1093/ajcp/aqaf115.
Gosnell HL, Roberts DE, Zhang X, Azzato EM, Jacubowski MA, Toro P, et al. Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns. Am J Clin Pathol. 2025 Dec 1;164(6):908–16.
Gosnell, Hailey L., et al. “Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns.Am J Clin Pathol, vol. 164, no. 6, Dec. 2025, pp. 908–16. Pubmed, doi:10.1093/ajcp/aqaf115.
Gosnell HL, Roberts DE, Zhang X, Azzato EM, Jacubowski MA, Toro P, Corredor G, Cheng Y-W, Dermawan J, Calderaro J, Graham RP, Kakar S, Allende DS. Hepatocellular adenomas with high-risk molecular alterations undetected by "high-risk" β-catenin and/or glutamine synthetase staining patterns. Am J Clin Pathol. 2025 Dec 1;164(6):908–916.
Journal cover image

Published In

Am J Clin Pathol

DOI

EISSN

1943-7722

Publication Date

December 1, 2025

Volume

164

Issue

6

Start / End Page

908 / 916

Location

England

Related Subject Headings

  • beta Catenin
  • Pathology
  • Mutation
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Immunohistochemistry
  • Humans
  • Glutamate-Ammonia Ligase
  • Female